Literature DB >> 12203362

CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.

Javier Mercapide1, Shi Yu Zhang, Xing Fan, Vicente Furió-Bacete, José Schneider, Iñigo López de la Osa, Arthur S Patchefsky, Andrés J P Klein-Szanto, Javier S Castresana.   

Abstract

Because of the relatively low incidence of lobular breast carcinoma, there are very few studies on the molecular characteristics of this breast cancer. In an attempt to improve its characterization, we investigated in a large collection of invasive lobular carcinomas (ILCs) the status of markers known to be involved in the better-studied invasive ductal carcinomas (IDC). In the current study we disposed of 80 well-characterized ILC cases. Gene amplification of cyclin D1 (CCND1) and c-erbB2-encoding gene (ERBB2) and expression of their gene products were studied by differential polymerase chain reaction (PCR) and immunohistochemistry, respectively. A comprehensive point mutation study of the phosphatase and tensin homolog tumor suppressor gene (PTEN) was pursued by single strand conformation polymorphism (SSCP)/sequencing analysis. The CCND1 gene was rarely amplified in ILC in spite of showing overexpression of the protein in 41% of tumors. Hence, unlike IDC, increase in gene dosage did not account for the protein excess. PTEN mutations were detected in ILC (truncating mutations) in around 2% of the tumors. Unlike IDC, ILC did not display ERBB2 overexpression and expression of the transcription factor E2F1 correlated inversely with tumor grade. The observed discrepancy in the pattern of the human oncogenes CCND1 and ERBB2, which are involved in the process of carcinogenesis of ductal tumors, appears to suggest a different molecular basis for development and progression of ILC. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203362     DOI: 10.1002/mc.10069

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  3 in total

1.  Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.

Authors:  Frédéric Guénard; Yvan Labrie; Geneviève Ouellette; Charles Joly Beauparlant; Paul Bessette; Jocelyne Chiquette; Rachel Laframboise; Jean Lépine; Bernard Lespérance; Roxane Pichette; Marie Plante; Francine Durocher
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

2.  HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

Authors:  A Vincent-Salomon; J-Y Pierga; J Couturier; C D d'Enghien; C Nos; B Sigal-Zafrani; M Lae; P Fréneaux; V Diéras; J-P Thiéry; X Sastre-Garau
Journal:  Br J Cancer       Date:  2007-01-30       Impact factor: 7.640

3.  Partial PTEN deletion is linked to poor prognosis in breast cancer.

Authors:  P Lebok; V Kopperschmidt; M Kluth; C Hube-Magg; C Özden; Taskin B; K Hussein; A Mittenzwei; A Lebeau; I Witzel; L Wölber; S Mahner; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; Ronald Simon; Guido Sauter; L Terracciano; R Krech; A von d Assen; V Müller; E Burandt
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.